Daiichi Sankyo and MassBio Team Up to Identify Cutting-Edge Science and Technology  

Sep 13, 2022

Daiichi Sankyo Pharma Day® to feature one-on-one meetings and open information session on November 2

On November 2, Daiichi Sankyo will team up with MassBio to host its 2022 Pharma Day®, during which the biopharmaceutical company will showcase its R&D strategy and connect with potential collaborators across the life sciences innovation ecosystem, particularly emerging biotechs.

Early-stage companies with drug candidates for oncology, rare diseases, and psychiatric and neurodegenerative diseases, as well as researchers affiliated with universities working on the same therapeutic areas, are encouraged to apply for a one-on-one meeting with Daiichi Sankyo representatives by September 27, 2022, at 11:59 PM EST.

“By uniting cutting-edge science and technology with a genuine interest in people, we develop high-quality, life-changing solutions for the patients of today and tomorrow,” says Stu Mackey, Global Head of Business Development at Daiichi Sankyo. “We create new standards of care as a team of experts.  Success relies on our people, health care providers and advocates each passionately bringing their own skill to bear. Our R&D partners are no exception, and we look forward to shared learning and building new connections at our 2022 Pharma Day.”

Following the one-on-one meetings on November 2, Daiichi Sankyo will host an in-person open information session for the latest insights on its R&D strategy, target therapeutic areas, and partnering capabilities. This session will be followed by a networking reception. To register for this event, please visit the MassBio website. As a reminder, this is a partnering event focused on science and innovation, and solicitations will not be permitted.

“Making connections is what MassBio does every day, and we look forward to introducing biotechs across the innovation ecosystem to Daiichi Sankyo’s world-class science and technology with the goal of addressing the unmet medical needs of patients around the world,” says MassBio CEO Joe Boncore.

Kendalle Burlin O’Connell, MassBio’s President & COO, added that Pharma Days empower “established and emerging life sciences companies to take full advantage of the world-leading biopharma cluster we have in Massachusetts to meet face-to-face, discover collaboration opportunities, and advance game-changing science.”

MassBio’s Pharma Days® provide unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies. Since 2010, MassBio has facilitated more than 1,000 connections between emerging entrepreneurs and established biopharmaceutical companies through Pharma Days® and other partnering initiatives.

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit: www.daiichisankyo.com.

See all MassBio News